Risperidone, Weight Gain, and an Elevated Prolactin
Ethan is 10 years 3 months old with autism spectrum disorder (level 2) and intellectual disability (FSIQ 62). Six months ago risperidone was started for aggression - hitting, biting, and throwing furniture at his day program up to five times weekly, with one staff injury. He is now on risperidone 1.5 mg daily (0.75 mg twice daily). His mother says he is calmer but "sleepy all morning." His weight has risen from 34 kg to 41.5 kg (BMI from the 65th to the 95th percentile). Fasting glucose 96 mg/dL, LDL 118 mg/dL, triglycerides 130 mg/dL, prolactin 42 ng/mL (reference under 18). No gynecomastia or galactorrhea. Liver enzymes normal. He lives with his mother and grandmother; his mother works two jobs, and his ABA program ended when funding lapsed four months ago.
1. How do you interpret the prolactin and metabolic findings, and what monitoring should have been in place?
Read the worked answer
Prolactin 42 ng/mL. Risperidone is the most prolactin-elevating second-generation antipsychotic, and children are more sensitive than adults. An asymptomatic elevation without gynecomastia, galactorrhea, or menstrual change does not require stopping the drug. It does require documenting the absence of symptoms, asking about breast tenderness and libido at each visit, and repeating the level if symptoms appear. Years of untreated hyperprolactinemia raise bone-density concerns.
Metabolic picture. A 7.5 kg gain in six months - roughly 22% of body weight - with BMI moving from the 65th to the 95th percentile is the most consequential finding here, more so in the long run than the aggression. Fasting glucose 96 mg/dL is normal but drifting; LDL 118 mg/dL is borderline; triglycerides 130 mg/dL are high for a child this age (normal under about 90).
Monitoring that should have happened: baseline and 3-month weight, BMI, waist circumference, blood pressure, fasting glucose or HbA1c, and lipids, then every 6-12 months - more often in children. Ask about sedation, akathisia, and tremor at every visit.
The sedation is diagnostically useful: it says the dose is higher than he needs and that the timing is wrong.
2. What are your next steps in medication management - continue, reduce, switch, or add metformin - and why?
Read the worked answer
Reassess the target before adding anything. You have partial efficacy (aggression down from five times weekly), a clear adverse effect (morning sedation), and a large iatrogenic weight gain. That combination argues for lowering exposure, not escalating.
Options, in order:
- Reduce to 1 mg at bedtime (from 0.75 mg twice daily). Bedtime dosing converts daytime sedation into a sleep benefit, and the lower total dose may preserve the aggression response.
- If weight gain continues, cross-taper to aripiprazole 2-5 mg - also FDA-approved for irritability in autism (ages 6-17), with a better metabolic profile but its own akathisia and weight-gain risk. Do not present it as "the safe one."
- Metformin 500 mg twice daily is a reasonable adjunct for antipsychotic-associated weight gain in youth; the effect is modest and it should never substitute for reducing the antipsychotic.
- Restart behavioral treatment. Medication without a functional behavior assessment treats a symptom whose function is unknown. Screen for pain (dental, constipation, reflux), sleep disruption, and escape or attention functions.
Do not add a second antipsychotic or a mood stabilizer for aggression without a defined target symptom and a stop date.
3. The mother asks you to write a letter supporting renewed ABA funding. What is your role and what belongs in that letter?
Read the worked answer
Yes, write it - advocacy is part of the role. Declining because "it isn't medical" would leave a ten-year-old on an antipsychotic that is partly compensating for a missing behavioral program.
A letter of medical necessity should include:
- The diagnoses and the specific target behaviors, quantified (frequency, duration, intensity, injuries to staff and family, property damage).
- The treatment history: what was tried, dose and duration, degree of response, and adverse effects - including the 7.5 kg gain, the sedation, and the elevated prolactin.
- A clear statement that medication is adjunctive and that without behavioral treatment the risk of injury, placement breakdown, and further dose escalation rises.
- The functional link: the lapse in ABA four months ago coincided with the period requiring antipsychotic initiation.
Coordinate rather than duplicate: send the day program a request for a functional behavior assessment and a behavior intervention plan, and ask the school to convene for an FBA/BIP if it has not. Be precise and avoid overstating certainty about outcomes; payer reviewers respond to specificity, not adjectives.
Also address the prescribing: use the same visit to document the dose reduction plan, so the letter and the chart tell one coherent story.